Skip to Content

Adverum Biotechnologies Inc ADVM

Morningstar Rating
$8.04 −0.21 (2.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADVM is trading at a 544% premium.
Price
$7.94
Fair Value
$56.76
Uncertainty
Extreme
1-Star Price
$592.95
5-Star Price
$5.63
Economic Moat
Vst
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADVM is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$8.25
Day Range
$7.858.38
52-Week Range
$7.4029.70
Bid/Ask
$8.01 / $9.00
Market Cap
$166.89 Mil
Volume/Avg
1.8 Mil / 288,929

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
121

Comparables

Valuation

Metric
ADVM
SWTX
KDNY
Price/Earnings (Normalized)
Price/Book Value
0.925.857.59
Price/Sales
111.85482.40
Price/Cash Flow
Price/Earnings
ADVM
SWTX
KDNY

Financial Strength

Metric
ADVM
SWTX
KDNY
Quick Ratio
8.976.215.72
Current Ratio
9.246.415.82
Interest Coverage
Quick Ratio
ADVM
SWTX
KDNY

Profitability

Metric
ADVM
SWTX
KDNY
Return on Assets (Normalized)
−41.52%−40.43%−37.41%
Return on Equity (Normalized)
−72.93%−46.62%−47.73%
Return on Invested Capital (Normalized)
−44.76%−50.77%−43.85%
Return on Assets
ADVM
SWTX
KDNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRfkdcpmvxMpds$586.1 Bil
VRTX
Vertex Pharmaceuticals IncLtpvkyxgTfdkn$113.7 Bil
REGN
Regeneron Pharmaceuticals IncVvfxfmgQgqlpn$108.2 Bil
MRNA
Moderna IncVxwvxkkzvVhl$50.9 Bil
ARGX
argenx SE ADRFtnbhkvCwzdk$22.0 Bil
BNTX
BioNTech SE ADRMfyxnmxtTbz$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncSxyzxrbkmHmjqpz$18.9 Bil
BMRN
Biomarin Pharmaceutical IncGdkztbbzKkdffs$14.6 Bil
INCY
Incyte CorpTpksycctySzjrgf$12.8 Bil
RPRX
Royalty Pharma PLC Class AKzskwgbftDvbnwtj$12.3 Bil

Sponsor Center